PRACTICAL ONCOLOGY JOURNAL ›› 2014, Vol. 28 ›› Issue (5): 391-395.doi: 10.11904/j.issn.1002-3070.2014.05.002

• Articles • Previous Articles     Next Articles

Expansion of new type cytokine induced killer cells in vitro with peripheral blood mononuclearcells in advanced breast cancer in PBMC

LU Xiangshi1,SONG Chuanjian2,CUI Jing1,QIN Li1,MEI Fen1,ZHANG Yanqiao1,ZHAO Juan1,LV Huimin1,ZHANG Benning3   

  1. 1.The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China;
    2.Chinese People's Armed Police Forces Heilongjiang Provincial Corps Hospital;
    3.Department of Immunology,Harbin Medical University
  • Received:2014-06-04 Online:2014-10-28 Published:2014-10-28

Abstract: Objective To investigate new type cytokine induced killer cells expansion using advanced breast cancer's peripheral blood.Methods peripheral blood mononuclear cells were isolated from 8 advanced breast cancer volunteers and co-cultured with Cytokine induced killer cells.These cells were placed in plastic flasks containing CIK-MediumTM supplemented with 10% auto-plasma in the presence of IL-2(1000IU/mL).The cultures were fed with CIK-MediumTM supplemented with IL-2 following the proliferation capacity.Cell proliferation was measured by cell counting during the cultivation.Fourteen days after cultivation,cell markers CD3/CD16/CD56 were examined by flow cytometry.51Cr and MTT assays were employed in cytotoxicity assays.Cytokines were assayed by ELISA method.Results CD16+,CD16+ CD56+,CD56+ CIK cells were 5.8~11.6% in 2×107 fresh PBMCs and 95.2~97.6% in co-cultured cells after 18 days cultivation.The in vitro expansion rate of new type cytokine induced killer cells was up to more than 8.2×108 in total,the cytotoxicity are effective killing cells against MCF7 and BT20 breast cancer cell lines.New type cytokine induced killer cells expanded from all PBMCs and secreted cytokines IFN- and TNF-.Conclusion The present culture could be useful to clarify the mechanisms of CIK cells expansion in vitro and feasible for breast cancer immmuno cell therapy.

CLC Number: